Operating cash-flow margin moved 619 bp higher
Operating cash-flow margin changed +619 basis points from the comparable as-filed period.
12.19%→18.38%2 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →MDB financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
R&D / revenue moved 302 bp lower
R&D / revenue changed -302 basis points from the comparable as-filed period.
30.73%→27.71%2 prior comparisons
Research & development increased 17.7%
Research & development changed +17.7% from the comparable as-filed period.
$181.7M→$213.9M2 prior comparisons
Free-cash-flow margin moved 596 bp higher
Free-cash-flow margin changed +596 basis points from the comparable as-filed period.
12.10%→18.06%2 prior comparisons
Capital expenditure increased 360.3%
Capital expenditure changed +360.3% from the comparable as-filed period.
$537,000→$2.5M3 prior comparisons
Cost of revenue increased 17.8%
Cost of revenue changed +17.8% from the comparable as-filed period.
$171.4M→$202.0M2 prior comparisons
Current assets increased 7.6%
Current assets changed +7.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$2.9B→$3.1B4 prior comparisons
Working capital / assets moved 186 bp lower
Working capital / assets changed -186 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
67.61%→65.74%4 prior comparisons
Total assets increased 6.7%
Total assets changed +6.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$3.5B→$3.8B4 prior comparisons
Current ratio decreased 14.6%
Current ratio changed -14.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
5.7→4.874 prior comparisons
Shares outstanding decreased 1.0%
Shares outstanding changed -1.0% from the comparable as-filed period. The change ranks at the 0th percentile of 8 prior comparable changes.
81,356,893→80,556,3418 prior comparisons
Stock-based compensation increased 6.1%
Stock-based compensation changed +6.1% from the comparable as-filed period.
$140.4M→$148.9M2 prior comparisons
Working capital increased 3.7%
Working capital changed +3.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$2.4B→$2.5B4 prior comparisons
Capex / revenue moved 23 bp higher
Capex / revenue changed +23 basis points from the comparable as-filed period.
0.09%→0.32%2 prior comparisons
Receivables / revenue moved 25 bp higher
Receivables / revenue changed +25 basis points from the comparable as-filed period.
59.12%→59.37%2 prior comparisons
Research & development increased 18.7%
Research & development changed +18.7% from the comparable as-filed period.
$168.8M→$200.4M3 prior comparisons
Net income changed across a sign change
Net income changed +111.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
-$37.6M→$4.4M2 prior comparisons
Capital expenditure increased 43.9%
Capital expenditure changed +43.9% from the comparable as-filed period. The change ranks at the 33th percentile of 6 prior comparable changes.
$1.6M→$2.3M6 prior comparisons
Capex / revenue moved 4 bp higher
Capex / revenue changed +4 basis points from the comparable as-filed period.
0.29%→0.34%2 prior comparisons
Stock-based compensation increased 4.1%
Stock-based compensation changed +4.1% from the comparable as-filed period.
$132.4M→$137.8M3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.